Immuron taps NZ dairy for colostrum production
07 May, 2012 by Dylan Bushell-EmblingImmuron (ASX:IMC) has signed a deal with dairy processing company Synlait covering the production of colostrum needed for its Travelan drug.
IQnovate to commercialise Nanosonics’ disinfection system
03 May, 2012 by Dylan Bushell-EmblingContract medical company IQnovate (ASX:IQN) has signed an MoU with Sydney's Nanosonics to help commercialise an ultrasound disinfection system.
Industry update from AusBiotech and PwC
03 May, 2012 by AusBiotechAusBiotech’s CEO, Dr Anna Lavelle and PricewaterhouseCoopers’ (PwC) Partner, Craig Lawn, sat down to discuss the state of the biotechnology and life sciences sector on webcast, including the impact of the R&D Tax Credit, changes in the market for capital as well as current and emerging trends.
AtCor launches improved blood pressure test
02 May, 2012 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has launched SphygmoCor XCEL, the newest iteration of its non-invasive central aortic blood pressure monitoring device.
Osprey Medical completes $20m IPO
02 May, 2012 by Dave KearnsShares in Osprey Medical (ASX:OSP), a US medical device company commercialising a product which uses Australian IP, began trading on the ASX on Wednesday.
Handheld plasma torch is like a lightsaber against bacteria
01 May, 2012 by Tim DeanA battery-powered handheld plasma torch developed by Australian and Chinese scientists has been shown to wipe out some of the nastiest bacteria on skin surfaces.
Set price fees for R&D Tax Incentive claims and advance findings
01 May, 2012 by AusBiotechThree tax-specialist accounting firms are offering AusBiotech members free consultations and set prices for R&D Tax Incentive claims and advance findings.
Ventus Medical launches $40m IPO
30 April, 2012 by Dylan Bushell-EmblingVentus Medical, a US-based company that develops products for sleep-disordered breathing, has launched a $40 million IPO on the ASX.
ResMed posts record $65m profit as US market strengthens
30 April, 2012 by Dylan Bushell-EmblingResMed (ASX:RMD) has revealed its March quarter profit grew 21% to $65 million, on the back of strong demand for its respiratory products in the Americas.
Allied Healthcare invests $1m into Coridon on back of herpes vaccine
30 April, 2012 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) has paid $1m to increase its stake in Coridon to 44.4%, due to the company's progress towards trials of its herpes vaccine.
New crop could transform Australian bioeconomy
27 April, 2012 by Tim DeanThe CSIRO has developed a variety of safflower with high oleic oil content that could become a key crop in Australia and around the world.
Swiss insurers to reimburse Clinuvel’s Scenesse
27 April, 2012 by Dylan Bushell-EmblingTwo Swiss insurers have agreed to reimburse Scenesse, developed by Clinuvel Pharmaceuticals (ASX:CUV), as a treatment for erythropoietic protoporphyria.
Annual AusBiotech-GSK Student Excellence Awards open now
26 April, 2012 by AusBiotechThe annual AusBiotech-GSK Student Excellence Awards aim to recognise and encourage promising research students and to raise awareness of research translation and applications.
CPI figures show PBS safety net is working: Medicines Australia
24 April, 2012 by Dylan Bushell-EmblingA 14.1% spike in the pharmaceutical component of the CPI is not down to a price hike, but instead shows that the PBS safety net is fulfilling its purpose, Medicines Australia's CEO says.
Mao’s Last Dancer to speak at AusMedtech
24 April, 2012 by AusBiotechThe 2012 AusMedtech national conference to be held in less than three weeks will feature inspirational speaker Li Cunxin, well known to many as Mao’s Last Dancer, amidst the program of over 40 speakers and panel sessions.
